AstraZeneca could buy Bristol's diabetes stake for more than $3B, report says

12/19/2013 | Reuters

Bristol-Myers Squibb reportedly is considering divesting to partner AstraZeneca its stake in their diabetes joint venture for more than $3 billion. The venture includes oral drugs Onglyza, Kombiglyze and Forxiga as well as injectable treatments Bydureon and Byetta, this article says. Neither firm commented on the report.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director of Behavioral Health Operations
Meridian Health Plan
Detroit, MI
Medical Director
PacificSource
Bend, OR
Clinical Appeals RN
MJHS
Brooklyn, NY
Director of Clinical Operations
Meridian Health Plan
Detroit, MI
Sr. Director, Regulatory Compliance Intelligence and Outreach
Johnson & Johnson
New Brunswick, NJ